ERBB2 and breast cancer: Accordingly, we observed that CD36 expression was strikingly high in HER2 + BC cases characterized by high expression of the basal marker CD44v6 [52], revealing enrichment of CD36 in tumor cells characterized by a mesenchymal/basal-like phenotype.